Research Topics
Species | David G PfisterSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposureBhuvanesh Singh
Laboratory of Epithelial Cancer Biology, Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York, USA
BMC Genet 3:22. 2002..We used comparative genomic hybridization (CGH) to screen for the genetic aberrations in 71 patients with head and neck squamous cell carcinoma and stratified the findings by the status of tobacco/alcohol exposure...- Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigmDavid G Pfister
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 24:1072-8. 2006..Cetuximab has activity in squamous cell carcinoma and enhances both chemotherapy and radiotherapy. We conducted a pilot phase II study of a new combined-modality paradigm of targeted therapy (cetuximab) with chemoradiotherapy... - Clinical practice. Surveillance strategies after curative treatment of colorectal cancerDavid G Pfister
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
N Engl J Med 350:2375-82. 2004 - Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled trialDavid G Pfister
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 28:2565-70. 2010..To determine whether acupuncture reduces pain and dysfunction in patients with cancer with a history of neck dissection. The secondary objective is to determine whether acupuncture relieves dry mouth in this population... - Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacyMichelle L Klem
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10022, USA
Int J Radiat Oncol Biol Phys 70:1100-7. 2008..With conventional techniques, significant toxicity can develop. Intensity-modulated radiotherapy (IMRT) has the potential to minimize the toxicity... - Predictors of outcome for advanced-stage supraglottic laryngeal cancerIan Ganly
Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Head Neck 31:1489-95. 2009..The objective of this study was to report our experience in the management of patients with advanced-stage supraglottic laryngeal carcinoma and to identify factors predictive of outcome... - Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancerRamesh Rengan
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Am J Clin Oncol 31:465-9. 2008..To examine the long-term neck failure outcome in patients with advanced head and neck cancer treated on larynx/organ preservation protocols at Memorial Sloan-Kettering Cancer Center... - Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynxJeannette Marie S Matsuo
Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Ann Surg 238:412-21; discussion 421-2. 2003..CONCLUSION: Regardless of the index treatment modality, primary tumor site, or T stage, a higher clinical N stage at the time of presentation independently and significantly increases the risk of DM in patients with SCCL... - Unresectable carcinoma of the paranasal sinuses: outcomes and toxicitiesBradford S Hoppe
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Int J Radiat Oncol Biol Phys 72:763-9. 2008..To evaluate long-term outcomes and toxicity in patients with unresectable paranasal sinus carcinoma treated with radiotherapy, with or without chemotherapy... - Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trialRichard L Bakst
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Radiat Oncol Biol Phys 80:148-53. 2011..To evaluate the feasibility of dose-painting intensity-modulated radiation therapy (DP-IMRT) with a hypofractionated regimen to treat nasopharyngeal carcinoma (NPC) with concomitant toxicity reduction... - Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancersNancy Y Lee
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 69:459-68. 2007..To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT)... - Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancersDaniel R Gomez
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 73:1096-103. 2009..To present our single-institution experience of intensity-modulated radiotherapy (IMRT) for oral cavity cancer... - Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PETJacobus F A Jansen
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Int J Radiat Oncol Biol Phys 82:299-307. 2012..Additionally, pretreatment multimodality imaging was evaluated for its efficacy in predicting short-term response to treatment... - Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancerYungpo Bernard Su
Department of a Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer J 12:182-8. 2006..To evaluate the ability of granulocyte-stimulating factor to decrease mucositis during postoperative radiotherapy for stage II-IV squamous head and neck cancer in a randomized, double-blind, placebo-controlled trial... - A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinomaNancy Y Lee
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 66:966-74. 2006..intensity-modulated radiotherapy (IMRT) in the setting of concurrent chemotherapy (CT) for locally advanced oropharyngeal carcinoma... - Postoperative complications of salvage total laryngectomyIan Ganly
Department of Head and Neck Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 103:2073-81. 2005..Multivariate analysis showed that primary CTRT was an independent predictor of local wound complications and pharyngocutaneous fistula... - Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastasesJacobus F A Jansen
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Radiat Oncol Biol Phys 77:1403-10. 2010.... - Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)Matthew G Fury
Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Anticancer Res 31:249-53. 2011..Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate saracatinib in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC)... - Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intentIman Osman
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2980-7. 2002..Prospective and larger studies are necessary before integration of these molecular markers as part of molecular staging and predictors for organ preservation or other outcomes... - Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinomaWilliam C Chen
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Cancer 106:820-9. 2006..This dose should serve as a Dmean constraint maximum for intensity-modulated radiotherapy treatment of nasopharynx carcinoma... - Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomasBhuvanesh Singh
Laboratory of Epithelial Cancer Biology, The Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Am J Pathol 161:365-71. 2002..6; 95% confidence interval = 1.9 to 29.6). The findings suggest that the 3q copy number status is an important marker for tumor progression and prognostication in patients with head and neck squamous cell carcinoma... - Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experienceStephanie A Terezakis
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 73:795-801. 2009..External beam radiotherapy (EBRT) plays a controversial role in the management of nonanaplastic thyroid cancer. We reviewed our institution's outcomes in patients treated with EBRT for advanced or recurrent nonanaplastic thyroid cancer... - Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancerSeng Chuan Ong
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Nucl Med 49:532-40. 2008..We investigated the clinical utility of 18F-FDG PET/CT in this setting... - A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancersMatthew G Fury
Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 25:165-72. 2007..This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers... - Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic reviewEric J Sherman
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, United States
Radiother Oncol 101:425-30. 2011..We evaluated our more recent experience with this approach, which included pathologic confirmation of all cases... - Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experienceSuzanne L Wolden
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 64:57-62. 2006..We now evaluate whether IMRT has resulted in improved outcomes for a larger cohort of patients with longer follow-up... - Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancerMatthew G Fury
Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Natl Compr Canc Netw 9:681-9. 2011..Avenues for ongoing research are also presented... - A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumorsMatthew G Fury
Division of Solid Tumor Oncology, Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immunol Immunother 57:155-63. 2008..Preclinical data suggest that co-administration of granulocyte-colony stimulating factor (G-CSF) may enhance the tumor cytotoxicity of bispecific antibodies... - Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinomaMatthew G Fury
Head and Neck Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Head Neck 33:1340-5. 2011..The purpose of this study is to determine if p16 immunoreactivity is associated with aberrant expression of components of the PI3 kinase pathway... - Viable tumor in postchemoradiation neck dissection specimens as an indicator of poor outcomeIan Ganly
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Head Neck 33:1387-93. 2011..The objective of this study was to determine the prognostic significance of viable tumor in postchemoradiation neck dissection specimens in patients with squamous cell carcinoma of the laryngopharynx... - Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experienceJeremy Setton
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Radiat Oncol Biol Phys 82:291-8. 2012..To update the Memorial Sloan-Kettering Cancer Center's experience with intensity-modulated radiotherapy (IMRT) in the treatment of oropharyngeal cancer (OPC)... - A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neckDavid G Pfister
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Invest New Drugs 20:123-7. 2002..Further investigation is warranted to determine the strength of the correlation between bryostatin-1 activity and PARP cleavage as a surrogate molecular marker of apoptosis... - Using patients as their own controls for cost evaluation of phase I clinical trialsEric J Sherman
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 22:1308-14. 2004..The results of our pilot study do not suggest that phase I trials always cost payers more than standard treatment... - The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongueCherry L Estilo
Dental Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:2300-6. 2003..3 amplification. This study aimed to delineate the role of SCCRO and PIK3CA in the pathogenesis of oral tongue SCC... - A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumorsMatthew G Fury
Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Chemother Pharmacol 59:467-75. 2007.... - 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung CancerChristopher G Azzoli
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 29:3825-31. 2011..Limitations of this data are such that a break from cytotoxic chemotherapy after a fixed course is also acceptable, with initiation of second-line chemotherapy at disease progression... - Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewedChristopher G Azzoli
J Natl Cancer Inst 99:828-9. 2007 - Head and neck cancer: recent advances and new standards of careArlene A Forastiere
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Clin Oncol 24:2603-5. 2006 - Induction chemotherapy for larynx preservation: patient selection or therapeutic effect?David G Pfister
J Clin Oncol 24:540-3. 2006 - Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomasJacques Bernier
Department of Radiation Oncology, Oncology Institute of Southern Switzerland, San Giovanni Hospital, CH 6504 Bellinzona, Switzerland
Crit Rev Oncol Hematol 56:353-64. 2005..There is remaining need for further research efforts that would enable scientists and clinicians to improve, in the next decade, the management of this complex entity of diseases... - American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibitionRowan T Chlebowski
Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 20:3328-43. 2002..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide... - American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancerDavid G Pfister
American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
J Clin Oncol 24:3693-704. 2006.... - Individualized treatment selection in patients with head and neck cancer: do molecular markers meet the challenge?Bhuvanesh Singh
J Clin Oncol 26:3114-6. 2008 - Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guidelineChristopher E Desch
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 23:8512-9. 2005..Chest x-rays, CBCs, and liver function tests are not recommended, and molecular or cellular markers should not influence the surveillance strategy based on available evidence... - American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003David G Pfister
American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 22:330-53. 2004 - Skin squamous cell cancer: the time is right for greater involvement of the medical oncologistDavid G Pfister
J Clin Oncol 25:1953-4. 2007 - Head and neck cancersArlene A Forastiere
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
J Natl Compr Canc Netw 3:316-91. 2005
Research Grants
- Acupuncture for shoulder syndrome after ca surgeryDavid Pfister; Fiscal Year: 2004..Data: Standard deviations, mean of control group, correlation between and within baseline and follow-up measures. ..